ClinicalTrials.gg
Active, not recruitingNCT07017777Updated Aug 5, 2026

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

A Phase 3 interventional study of PCV13i and Prevnar 13 in Pneumococcal Infections, Streptococcal Infections and Bacterial Infections, sponsored by CanSino Biologics Inc.. Active, not recruiting at 3 sites in Thailand. Open to participants aged 6 Weeks to 2 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by CanSino Biologics Inc. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
6 Weeks to 2 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Pneumococcal Infections with a site in Thailand — 1 open to participants now, 3 under way, 3 of them phase 3. Pneumococcal Infections · Thailand.

Enrollment
8th of 11
600 · median 882
Started
2025
with 1 other
Phase 3
11 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
CanSino Biologics Inc.

Among the 11 studies in Pneumococcal Infections with a site in Thailand, this one is the 8th largest by enrollment, is one of 2 that started in 2025, is one of 11 in phase 3, and was the 10th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 11 studies in Pneumococcal Infections with a site in Thailand is open now. Recruiting first, the newest first:

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Weeks to 2 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pneumococcal Infections with a site in Thailand, or all of them as a file.
02

Study summary

This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a 2+1 schedule (2 months, 4 months and 12-15 months). The trial will enroll approximately 600 healthy infants aged 2 months (at least 6 weeks) who will be randomly assigned in a 1:1 ratio to receive either the experimental or control vaccine, with 100 in each group (200 in total) randomized to subgroups and subject to additional immunogenicity assessments. All participants will be evaluated for solicited adverse events for 7 days and unsolicited adverse events for 30 days post each vaccination. Immunogenicity evaluation will be performed in all participants at baseline and post the booster dose, while the sub-cohort participants will be evaluated for post primary series immunogenicity additionally.

03

Conditions studied

  • Pneumococcal Infections
  • Streptococcal Infections
  • Bacterial Infections

Keywords

  • PCV13i
  • 13 valent Pneumococcal conjugate vaccine
  • Pneumococcal infections
  • 2 months of age
  • Safety
  • Immunogenicity
04

Who can participate

Ages eligible
6 Weeks to 2 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy infants with stable clinical conditions aged 2 months (42-90 days) at the time of screening, based on medical history and clinical assessment by the investigator. Infants will be eligible starting from the day they turn 6 weeks of age.
  • Infant's parent or legal guardian must be able and willing to provide for the infant's participation in the study.
  • Participants and their parent or legal guardian must demonstrate the ability to comply with all trial procedures and be available for the entire follow-up duration.
  • The infant's parent or legal guardian must have an easily identifiable and stable place of residence within the study area, be available for the duration of trial participation, and have access to a reliable means of telephone contact for communication with the study team.

Exclusion criteria

Exclusion Criteria for the first dose:

  • Infants born at \<35 weeks of gestation.
  • Infants who have previously received any pneumococcal vaccine.
  • Infants currently participating in or who have recently participated in another interventional clinical trial.
  • Infants with an axillary temperature of ≥37.8°C at the time of enrollment (the participant must be deferred until recovery. The visit may be rescheduled when this criterion is met.)
  • Infants with any congenital abnormalities, chronic medical conditions, or genetic disorders, severe malnutrition, inherited disease and others, that in the investigator's judgment, may interfere with the study outcomes.
  • History of anaphylactic shock
  • History of allergic disease or history of a serious reaction to any prior vaccination or known to any component of the experimental and control vaccine
  • History of epilepsy and convulsions.
  • Have received treatment, cytotoxic treatment, systemic treatment for more than 2 weeks, etc. (excluding local treatment, surface treatment of acute non-concurrent dermatitis, or spray treatment of allergic rhinitis).
  • Received or planned to receive blood/plasma products or immunoglobulins throughout the study period or prior to study vaccination.
  • History of coagulation disorders or blood conditions that could cause anemia or excess bleeding as judged by the investigator.
  • Infants with known or suspected immunodeficiency, as determined by medical history and/or physical examination.
  • Administration of other vaccines within 7 days prior to enrollment.
  • Any history or current evidence of a condition or therapy that could confound study results, interfere with participation, or is not in the best interest of the participant, as judged by the investigator.
  • The participant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the contract research organization (CRO), the investigator, or study site personnel.
  • Any other condition or situation that, in the investigator's judgment, might interfere with the study or pose additional risks to the participant.

Individual termination criteria for subsequent doses:

  • Severe allergic reaction after the previous vaccination.
  • Serious adverse events caused by the previous vaccination that is not suitable for subsequent vaccination(s) as judged by the investigator.
  • Newly identified symptoms or newly occurred cases after the first vaccination that do not meet the inclusion criteria for the first dose, or that meet the exclusion criteria for the first dose. The decision to discontinue participation is determined by the investigator.
  • Other reasons for exclusion considered by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (PCV13i)

    Intramuscular Injection, 0.5ml

    Biological: PCV13i

  • Active comparator
    Pneumococcal 13-valent Conjugate Vaccine (Prevnar 13)

    Intramuscular Injection, 0.5ml

    Biological: Prevnar 13

Interventions

  • BiologicalPCV13i

    3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)

  • BiologicalPrevnar 13

    3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mL

    Time frame: 30 days after the booster dose

  2. Incidence of solicited local and systemic adverse events (AEs)

    Time frame: Within 7 days after each dose of vaccination

Secondary outcomes

  1. Incidence of unsolicited adverse events

    Time frame: Within 30 days after each dose of vaccination

  2. The number of serious adverse events (SAEs)

    Time frame: Through study completion, an average of 16-19 months

  3. The geometric mean concentration (GMC) of Serotype-specific IgG in all participants

    Time frame: Before vaccination and 30 days after the booster dose

  4. Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mL in Sub-cohort A participants

    Time frame: 30 days after the primary series

  5. Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mL in Sub-cohort B participants

    Time frame: Before the booster dose

  6. The geometric mean concentration (GMC) of Serotype-specific IgG in Sub-cohort A participants

    Time frame: 30 days after the primary series

  7. The geometric mean concentration (GMC) of Serotype-specific IgG in Sub-cohort B participants

    Time frame: Before the booster dose

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 15 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartActual
Nov 14, 2025
Primary completionEst.
Feb 15, 2027
CompletionEst.
May 15, 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07017777
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Nov 14, 2025
Primary completion
Feb 15, 2027 (estimated)
Completion
May 15, 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Supattra Rungmaitree, Doctor of Medicine
principal investigator · Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion